Pfizer Inc. $PFE Shares Bought by Signet Investment Advisory Group Inc.

Signet Investment Advisory Group Inc. lifted its stake in Pfizer Inc. (NYSE:PFE) by 2.4% in the 2nd quarter, Holdings Channel reports. The firm owned 135,312 shares of the biopharmaceutical company’s stock after purchasing an additional 3,194 shares during the quarter. Pfizer accounts for approximately 1.7% of Signet Investment Advisory Group Inc.’s portfolio, making the stock its 23rd biggest position. Signet Investment Advisory Group Inc.’s holdings in Pfizer were worth $3,280,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. GKV Capital Management Co. Inc. acquired a new stake in shares of Pfizer in the first quarter valued at about $27,000. Curio Wealth LLC lifted its stake in shares of Pfizer by 36,600.0% in the second quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 1,098 shares during the period. North Capital Inc. acquired a new stake in shares of Pfizer in the first quarter valued at about $28,000. Bayforest Capital Ltd acquired a new stake in shares of Pfizer in the first quarter valued at about $28,000. Finally, Harbor Asset Planning Inc. acquired a new stake in shares of Pfizer in the second quarter valued at about $29,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently commented on PFE shares. UBS Group reiterated a “neutral” rating and issued a $28.00 price objective on shares of Pfizer in a research note on Wednesday, October 1st. Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a research note on Wednesday, October 8th. Bank of America raised their price objective on shares of Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research note on Friday, October 3rd. Citigroup lifted their target price on shares of Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 6th. Finally, Wall Street Zen cut shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday, September 28th. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Pfizer currently has a consensus rating of “Hold” and a consensus price target of $28.13.

Pfizer Stock Performance

Shares of PFE opened at $24.76 on Tuesday. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. The stock has a market cap of $140.75 billion, a P/E ratio of 13.17, a PEG ratio of 0.82 and a beta of 0.55. The company has a 50-day moving average of $24.86 and a two-hundred day moving average of $24.21. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $29.17.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. The company had revenue of $14.65 billion during the quarter, compared to analysts’ expectations of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The firm’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, research analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 7th will be issued a dividend of $0.43 per share. The ex-dividend date is Friday, November 7th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.9%. Pfizer’s payout ratio is 91.49%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.